logo
Asia shares sideswiped by US economic jitters, oil slips

Asia shares sideswiped by US economic jitters, oil slips

Reuters16 hours ago
SYDNEY, Aug 4 (Reuters) - Asian share markets followed Wall Street lower on Monday as fears for the U.S. economy returned with a vengeance, spurring investors to price in an almost certain rate cut for September and undermining the dollar.
Some early resilience in U.S. stock futures and a continued retreat in oil prices did help limit the losses, but the bleak message from the July payrolls report was hard to ignore.
Not only had revisions meant payrolls were 290,000 below where investors had thought they would be, but the three-month average slowed to just 35,000 from 231,000 at the start of the year.
"The report brings payroll growth closer in line with big data indicators of job gains and the broader growth dataset, both of which have slowed significantly in recent months," noted analysts at Goldman Sachs.
"Taken together, the economic data confirm our view that the U.S. economy is growing at a below-potential pace."
Neither did the reaction of President Donald Trump instil confidence, as the firing of the head of Labor Statistics threatened to undermine confidence in U.S. economic data.
Likewise, news that Trump would get to fill a governorship position at the Federal Reserve early added to worries about the politicisation of interest rate policy.
Analysts assume the appointee will be loyal to Trump alone, though the president did grudgingly concede that Fed Chair Jerome Powell would likely see out his term.
"It opens the prospect of broader support on the Fed Board for lower rates sooner rather than later," said Ray Attrill, head of FX research at NAB. "Fed credibility, and the veracity of the statistics on which they base their policy decisions, are both now under the spotlight."
Markets moved quickly to price in a lot more easing with the probability of a September rate cut swinging to 90%, from 40% before the jobs report.
Futures extended the rally on Monday to imply 65 basis points of easing by year-end, compared to 33 basis points pre-data.
Markets have essentially already eased for the Fed with two-year Treasury yields down another 4 basis points at 3.661%. They tumbled almost 25 basis points on Friday in the biggest one-day drop since August last year.
The prospect of lower borrowing costs offered some support for equities and S&P 500 futures inched up 0.1%, while Nasdaq futures rose 0.2%.
Asian share markets, however, were still catching up with Friday's retreat and the Nikkei (.N22%), opens new tab fell 2.1%, while South Korea (.KS11), opens new tab dipped 0.2%.
MSCI's broadest index of Asia-Pacific shares outside Japan (.MIAPJ0000PUS), opens new tab broke the mould and firmed 0.3%.
Wall Street has also taken comfort in an upbeat results season. Around two-thirds of the S&P 500 have reported and 63% have beaten forecasts. Earnings growth is estimated at 9.8%, up from 5.8% at the start of July.
Companies reporting this week include Disney (DIS.N), opens new tab, McDonald's (MCD.N), opens new tab, Caterpillar (CAT.N), opens new tab and some of the large pharmaceutical groups.
The dismal U.S. jobs data did put a dent in the dollar's crown of exceptionalism, snuffing out what had been a promising rally for the currency.
The dollar dipped 0.1% to 147.24 yen , having shed an eye-watering 2.3% on Friday, while the euro stood at $1.1585 after bouncing 1.5% on Friday.
The dollar index was pinned at 98.659 , having been toppled from last week's top of 100.250.
Sterling was more restrained at $1.3287 as markets are 87% priced for the Bank of England to cut rates by a quarter point at a meeting on Thursday.
The BoE board itself is expected to remain split on easing, while markets still favour two further cuts by the middle of next year.
In commodity markets, gold was flat at $3,361 an ounce , having climbed more than 2% on Friday.
Oil prices extended their latest slide as OPEC+ agreed to another large rise in output for September, which completely reverses last year's cuts of 2.2 million barrels per day.
Brent dropped 0.6% to $69.24 a barrel, while U.S. crude also fell 0.6% to $66.93 per barrel.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

UK hedge fund Marshall Wace posted mixed returns for July, source says
UK hedge fund Marshall Wace posted mixed returns for July, source says

Reuters

time19 minutes ago

  • Reuters

UK hedge fund Marshall Wace posted mixed returns for July, source says

LONDON, Aug 4 (Reuters) - British hedge fund Marshall Wace returned mixed results in two of its funds in July, a source close to the matter told Reuters on Monday. Co-founded by British financier Paul Marshall, the $76.9 billion firm returned 1.6% in July culminating in a 6.1% performance for 2025 so far in its Eureka Fund, the source said. The hedge fund's Market Neutral Tops fund returned -0.22% for July and is up 10.99% year to date the source added. Systematic stock trading hedge funds, like Marshall Wace, are up roughly 10% for 2025 so far, said Goldman Sachs on Monday.

Netherlands to start NATO's new Ukraine weapons finance scheme with $578 mln payment
Netherlands to start NATO's new Ukraine weapons finance scheme with $578 mln payment

Reuters

time21 minutes ago

  • Reuters

Netherlands to start NATO's new Ukraine weapons finance scheme with $578 mln payment

AMSTERDAM, Aug 4 (Reuters) - The Netherlands will be the first contributor to NATO's new "Priority Ukraine Requirements List" (PURL) financing mechanism for Ukraine weapons with a 500 million euros ($578 million) payment, the Dutch defence ministry said on Monday. U.S. President Donald Trump said last month the U.S. would supply weapons to Ukraine, paid for by European allies, but did not provide details on how this would work. Reuters reported on Friday that NATO countries, Ukraine, and the U.S. were developing a new Ukraine weapons financing mechanism. ($1 = 0.8649 euros)

Wegovy maker Novo hit with investor class action over revenue forecast cut
Wegovy maker Novo hit with investor class action over revenue forecast cut

Reuters

time21 minutes ago

  • Reuters

Wegovy maker Novo hit with investor class action over revenue forecast cut

Aug 4 (Reuters) - Novo Nordisk ( opens new tab, maker of the weight-loss drug Wegovy, has been sued in U.S. court by investors claiming the Danish pharmaceutical giant misled them with optimistic growth forecasts and minimized competition risks in the obesity market. The proposed class action lawsuit, opens new tab was filed on Friday in the federal court in New Jersey following a sharp decline in the company's stock price. Investors knocked $70 billion off Novo Nordisk's market value on a single trading day last week. Novo last week in a statement said it was lowering its 2025 sales and operating profit outlook due to lower growth expectations in the second half in the United States for Wegovy in the obesity market and the drugmaker's Ozempic in the diabetes market. Novo said its updated sales outlook for Wegovy stemmed from the 'persistent' use of compounded versions of the drug, competition and what it described as slower-than-expected market expansion. A representative from Novo and an attorney for the plaintiff did not immediately respond to requests for comment on Monday about the investor lawsuit. The lawsuit was filed on behalf of potentially thousands of investors who purchased Novo's stock between May 7, 2025 and July 28. The tight supply of Wegovy in the United States in 2022 prompted U.S. regulators to temporarily allow the sale of cheaper, compounded versions of the drug, known chemically as semaglutide. The U.S. Food and Drug Administration in February removed Wegovy from the agency's shortage list. Novo in June said it was ending a partnership with telehealth company Hims & Hers that began in late April, citing Hims' alleged improper marketing and sales of Wegovy copies. Novo accused Hims of 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' Hims CEO Andrew Dudum in a response accused Novo management of misleading the public and making anticompetitive demands. The case is Eric Barta v. Novo Nordisk et al, U.S. District Court, District of New Jersey, No. 2:25-cv-14045. For plaintiff: Adam Apton of Levi & Korsinsky For defendants: No appearances yet Read more: Novo Nordisk shares dip further as Wegovy gains nearly erased Hims & Hers hit with investor lawsuits after Novo ends Wegovy partnership Wegovy maker Novo faces fee demand after losing copycat drug lawsuit Ozempic copies restricted after US judge denies injunction

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store